In a previous study, it was shown that CDYL2 recruits G9a and EZH2 to epigenetically repress miR124, which promotes NF-κB and STAT3 activation and negatively impacts the prognosis of breast cancer[137]. This evidence concerns the gene EZH2 and breast cancer.